Search
Azilsartan medoxomil
go.drugbank.com/drugs/DB08822ApprovedInvestigationalAzilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. … It is also available in a combination product with [chlorthalidone].
Mixtures: EDARBI CLD®, EDARBI CLD® 40MG/12.5MGCategories: Angiotensin 2 Receptor Blocker, P-glycoprotein inhibitorsTetraethylammonium
go.drugbank.com/drugs/DB08837InvestigationalAs an experimental agent, tetraethylammonium is used in its salt forms such as tetraethylammonium chloride and tetraethylammonium bromide. … The most common use of tetraethylammonium presently is as a pharmacological research agent that blocks selective potassium channels.
Categories: MATE 1 Substrates, MATE 2 SubstratesSerotonin
go.drugbank.com/drugs/DB08839InvestigationalNutraceuticalFor temporary relief of nervousness, anxiety, mood swings, joint pains, weakness, drowsiness, itching and lethargy. Not evaluated by the FDA, homeopathic product.
Synonyms: 3-(2-Aminoethyl)-1H-indol-5-ol, 5-HTInternational brands: 5-HTP, Super 5-HTPEllagic acid
go.drugbank.com/drugs/DB08846InvestigationalEllagic acid is an investigational drug studied for treatment of Follicular Lymphoma (phase 2 trial), protection from brain injury of intrauterine growth restricted babies (phase 1 and 2 trial), improvement … Ellagic acid is present in several fruits such as cranberries, strawberries, raspberries, and pomegranates.
Categories: Cytochrome P-450 CYP2E1 Inhibitors, Heterocyclic Compounds, 1-RingFingolimod
go.drugbank.com/drugs/DB08868ApprovedInvestigational[A176474] Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. … Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects.
Categories: P-glycoprotein inducers, Cytochrome P-450 SubstratesProducts: AXIMOD-MS ® 0.5 MG CÁPSULAS, DROPTON®Cabozantinib
go.drugbank.com/drugs/DB08875ApprovedInvestigationalCabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. … It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer.
Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexVemurafenib
go.drugbank.com/drugs/DB08881ApprovedInvestigationalVemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E.[A31269] It exerts its function by binding to the ATP-binding domain of the mutant BRAF. … After approval, Roche in collaboration with Genentech launched a broad development program. [L1012]
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: ZELBORAF ® TABLETAS LACADAS DE 240 MGMirabegron
go.drugbank.com/drugs/DB08893ApprovedInvestigationalMirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. … It is unique amongst overactive bladder treatment options in that, unlike other treatments such as [solifenacin] and [darifenacin], it lacks significant antimuscarinic activity,[A232553] which is responsible
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: MYRBETRIC® 50 MG TABLETAS DE LIBERACION PROLONGADA, MYRBETRIC® 25 MG TABLETAS DE LIBERACION PROLONGADATofacitinib
go.drugbank.com/drugs/DB08895ApprovedInvestigationalKnown adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer. … Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingProducts: XELJANZ®5MG, เซลแจนซ์ (ยาเม็ด 5 มก.)Ponatinib
go.drugbank.com/drugs/DB08901ApprovedInvestigationalPonatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic IndexProducts: ICLUSIG® 15 MG TABLETAS RECUBIERTAS